#ASCO17: Incyte Gets a Boost from a Series of Positive Data Snapshots for Its Epacadostat/Keytruda Combo

Excerpt:

“Wednesday evening brought with it the data dump on abstracts for the upcoming annual ASCO confab in Chicago in early June, and the big preliminary winner — not a big surprise — was Incyte, with a slate of new data points underscoring the potential of its leading, late-stage IDO1 drug epacadostat in combination with Merck’s Keytruda.

“Incyte shares $INCY swelled 9.5% in after-market trading as investors got a glimpse of things to come, with a 30%-plus response rate for a full slate of combination studies that are now pushing into Phase III development.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.